P. Bonneau

发表

Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions

A. Tropsha, Alexander Sedykh, D. Fourches, 2013, Pharmaceutical Research.

Scaffold hopping in the rational design of novel HIV-1 non-nucleoside reverse transcriptase inhibitors.

P. Bonneau, C. Yoakim, S. LaPlante, 2007, Bioorganic & medicinal chemistry letters.

Development of Specific “Drug‐Like Property” Rules for Carboxylate‐Containing Oral Drug Candidates

O. Hucke, P. Bonneau, A. Böcker, 2010, ChemMedChem.

An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

Steven R. LaPlante, P. Bonneau, D. Lamarre, 2003, Nature.

Unique Thermodynamic Response of Tipranavir to Human Immunodeficiency Virus Type 1 Protease Drug Resistance Mutations

L. M. Amzel, P. Bonneau, L. Amzel, 2007, Journal of Virology.

Engineering the S2 subsite specificity of human cathepsin S to a cathepsin L- and cathepsin B-like specificity.

P. Bonneau, D. Brömme, A. C. Storer, 1994, The Journal of biological chemistry.

Compound aggregation in drug discovery: implementing a practical NMR assay for medicinal chemists.

P. Bonneau, S. LaPlante, R. Coulombe, 2013, Journal of medicinal chemistry.

Integrated strategies for identifying leads that target the NS3 helicase of the hepatitis C virus.

Araz Jakalian, Xiang Li, Steven R. LaPlante, 2014, Journal of medicinal chemistry.

Preclinical Profile of BI 224436, a Novel HIV-1 Non-Catalytic-Site Integrase Inhibitor

J. Duan, M. Garneau, P. Bonneau, 2014, Antimicrobial Agents and Chemotherapy.

Inhibition of HIV-1 capsid assembly: optimization of the antiviral potency by site selective modifications at N1, C2 and C16 of a 5-(5-furan-2-yl-pyrazol-1-yl)-1H-benzimidazole scaffold.

J. Duan, O. Hucke, M. Garneau, 2012, Bioorganic & medicinal chemistry letters.

Molecular dynamics simulations and structure-based rational design lead to allosteric HCV NS5B polymerase thumb pocket 2 inhibitor with picomolar cellular replicon potency.

O. Hucke, P. Bonneau, C. Brochu, 2014, Journal of medicinal chemistry.

Thiotetrazole alkynylacetanilides as potent and bioavailable non-nucleoside inhibitors of the HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases.

J. Duan, M. Garneau, P. Bonneau, 2007, Bioorganic & medicinal chemistry letters.

Design of fluorogenic peptide substrates for human cytomegalovirus protease based on structure-activity relationship studies.

P. Bonneau, M. Poupart, A. Pelletier, 1998, Analytical biochemistry.

Improved purification protocol of the HSV-1 protease catalytic domain, using immunoaffinity.

P. Bonneau, M. Massariol, G. McKercher, 1997, Biochemistry and cell biology = Biochimie et biologie cellulaire.

Inhibition of Human Cytomegalovirus Protease by Monocyclic β-Lactam Derivatives: Kinetic Characterization Using a Fluorescent Probe

P. Bonneau, S. LaPlante, W. Ogilvie, 1999 .

Characterization of the Human Cytomegalovirus Protease As an Induced-Fit Serine Protease and the Implications to the Design of Mechanism-Based Inhibitors

P. Bonneau, S. LaPlante, N. Aubry, 1999 .

Unique Thermodynamic Response of Tipranavir to Human Immunodeﬁciency Virus Type 1 Protease Drug Resistance Mutations (cid:1)

P. Bonneau, L. Amzel, E. Freire, 2007 .

Novel nevirapine-like inhibitors with improved activity against NNRTI-resistant HIV: 8-heteroarylthiomethyldipyridodiazepinone derivatives.

J. Duan, P. Bonneau, C. Yoakim, 2004, Bioorganic & medicinal chemistry letters.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 1: addressing configurational instability through scaffold modification.

O. Hucke, P. Bonneau, S. Morin, 2013, Bioorganic & medicinal chemistry letters.

Functional expression of human cathepsin S in Saccharomyces cerevisiae. Purification and characterization of the recombinant enzyme.

C. Peters, P. Bonneau, T. Vernet, 1993, The Journal of biological chemistry.

An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

P. Bonneau, D. Lamarre, P. Anderson, 2003 .

An NS 3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus

P. Bonneau, D. Lamarre, P. Anderson, 2003 .

Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly.

O. Hucke, P. Bonneau, C. Yoakim, 2011, Bioorganic & medicinal chemistry letters.

Discovery and structural characterization of a new inhibitor series of HIV-1 nucleocapsid function: NMR solution structure determination of a ternary complex involving a 2:1 inhibitor/NC stoichiometry.

O. Hucke, P. Bonneau, S. Titolo, 2013, Journal of molecular biology.

Optimization of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of HIV capsid assembly inhibitors 2: structure-activity relationships (SAR) of the C3-phenyl moiety.

J. Duan, O. Hucke, M. Garneau, 2013, Bioorganic & medicinal chemistry letters.

Investigation on the role of the tetrazole in the binding of thiotetrazolylacetanilides with HIV-1 wild type and K103N/Y181C double mutant reverse transcriptases.

P. Bonneau, C. Yoakim, R. Coulombe, 2009, Bioorganic & medicinal chemistry letters.

HIV and AIDS Therapeutics

P. Bonneau, B. Simoneau, 2007 .

A new serine-protease fold revealed by the crystal structure of human cytomegalovirus protease

P. Bonneau, L. Tong, M. Massariol, 1996, Nature.

NMR structural characterization of peptide inhibitors bound to the Hepatitis C virus NS3 protease: design of a new P2 substituent.

Martin Poirier, P. Bonneau, D. Lamarre, 2004, Journal of medicinal chemistry.

Discovery of BI 224436, a Noncatalytic Site Integrase Inhibitor (NCINI) of HIV-1.

Araz Jakalian, Sébastien Morin, Yves Bousquet, 2014, ACS medicinal chemistry letters.

Resistance to HIV Non-Nucleoside Reverse Transcriptase Inhibitors

R. Elston, P. Bonneau, 2009 .

Aligning Potency and Pharmacokinetic Properties for Pyridine-Based NCINIs.

J. Duan, M. Garneau, P. Bonneau, 2016, ACS medicinal chemistry letters.

Resistance to HIV-1 Protease Inhibitors

R. Elston, P. Bonneau, L. Doyon, 2009 .

HTS Promiscuity Analyses for Accelerating Decision Making

Alexander Böcker, Paul J Edwards, Pierre R Bonneau, 2011, Journal of biomolecular screening.

Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection.

P. Bonneau, D. Lamarre, H. Nar, 2003, Angewandte Chemie.

Peptidomimetic inhibitors of the human cytomegalovirus protease.

P. Bonneau, C. Yoakim, C. Chabot, 1997, Journal of medicinal chemistry.

Alteration of the specificity of subtilisin BPN' by site-directed mutagenesis in its S1 and S1' binding sites

P. Bonneau, J. B. Jones, D. Estell, 1991 .

Human Intestinal Transporter Database: QSAR Modeling and Virtual Profiling of Drug Uptake, Efflux and Interactions

A. Tropsha, Alexander Sedykh, D. Fourches, 2013, Pharmaceutical Research.

Unique Thermodynamic Response of Tipranavir to HIV-1 Protease Drug Resistance Mutations

P. Bonneau, L. Amzel, E. Freire, 2007 .

Novel 8-substituted dipyridodiazepinone inhibitors with a broad-spectrum of activity against HIV-1 strains resistant to non-nucleoside reverse transcriptase inhibitors.

J. Duan, M. Garneau, P. Bonneau, 2005, Journal of Medicinal Chemistry.

E-64 Analogs as Inhibitors of Cathepsin L and Cathepsin S: Importance of the S2-P2 Interactions for Potency and Selectivity1

P. Bonneau, H. Kirschke, A. C. Storer, 1994 .

A new serine protease fold revealed by the crystal structure of human cytomegalovirus protease

P. Bonneau, L. Tong, M. Massariol, 1996 .

Monitoring drug self-aggregation and potential for promiscuity in off-target in vitro pharmacology screens by a practical NMR strategy.

P. Bonneau, S. LaPlante, R. Coulombe, 2013, Journal of medicinal chemistry.

Contribution to activity of histidine-aromatic, amide-aromatic, and aromatic-aromatic interactions in the extended catalytic site of cysteine proteinases.

E. Purisima, P. Bonneau, D. Y. Thomas, 1996, Biochemistry.

A novel inhibitor-binding site on the HIV-1 capsid N-terminal domain leads to improved crystallization via compound-mediated dimerization.

P. Bonneau, S. Titolo, A. Faucher, 2013, Acta crystallographica. Section D, Biological crystallography.

Evidence of a conformational change in the human cytomegalovirus protease upon binding of peptidyl-activated carbonyl inhibitors.

P. Bonneau, S. LaPlante, M. Massariol, 1997, Biochemistry.